Devin Quinlan

435 posts

Devin Quinlan banner
Devin Quinlan

Devin Quinlan

@devinquinlan

🧬🚀 Biotech VC @ https://t.co/7fUi8JnEvT Breakout Fund.👨‍🔬Biological Engineering PhD @MIT. 🙆‍♂️ Fmr performer/director @improvboston. he/him. 🌶 Hot takes are my own

Cambridge, MA Katılım Aralık 2011
347 Takip Edilen916 Takipçiler
Devin Quinlan
Devin Quinlan@devinquinlan·
Grateful to be part of the "Survivor Tribal Council" of Academy Members for this year's NEVY awards in Life Sciences! Excited for the companies that were selected - hope you can join us to see the winners announced on December 5th! @NewEnglandVC bit.ly/academies24
English
0
1
4
356
Michael Torres
Michael Torres@Mykalt45·
A few different ideas could be applied. Initial thought was simply to turn cold tumors hot by increasing neo-antigen production by a method that’s relatively simple. Beyond that, you could pair with any other IO therapy desired, if needed, but could be efficacious on its own and wouldn’t need to be customized.
English
1
0
0
82
Devin Quinlan
Devin Quinlan@devinquinlan·
@hannu @jeffvandermeer To me - reminded me of a combination of the last of us + iRobot. The idea of machines becoming sentient is very much science fiction.
English
0
0
0
69
Devin Quinlan
Devin Quinlan@devinquinlan·
So much of scientific research is focused on bringing science fiction to life. It’s amazing how many of our most important innovations first came from the minds of writers
Christie Wilcox@NerdyChristie

This robot is alive. Incorporated into its electronics are living fungal tissues that change the robot's behavior when exposed to intense light. That and more of the best from @ScienceMagazine and science in this edition of #ScienceAdviser: science.org/content/articl…

English
2
0
15
8.1K
Devin Quinlan
Devin Quinlan@devinquinlan·
@varma_ashwin97 A few reasons: - disconnect between early vs late stage investors in the life of a company (early investors often sell before commercialization) - desire to mitigate technical risks by prioritizing programs with validated biology - being wrong/ getting unlucky
English
0
0
1
249
Ashwin Varma, MD
Ashwin Varma, MD@varma_ashwin97·
@devinquinlan Question, why do presumably rational, profit making capitalists invest in these minimally differentiated drugs, if they are unlikely to be profitable?
English
3
0
2
178
Devin Quinlan
Devin Quinlan@devinquinlan·
Great examples of why first in class and best in class are so important in our industry - there are very few drugs that win on a given mechanism, in many cases just 1. A ton of capital being spent developing insufficiently differentiated products that are perceived as “low risk”
Professor Oak@Prof_Oak_

What's driving that bimodal distribution? Differentiation, or lack thereof Order of entry is incredibly important for undifferentiated drugs. Conversely, it plays a far lesser role for differentiated products. In both cases, avg. benchmarks under / overstate potl. share (3/4)

English
2
1
32
5.9K
Devin Quinlan retweetledi
CNBC's Fast Money
CNBC's Fast Money@CNBCFastMoney·
The disruptive potential for gene and cell therapies is taking center stage in the biotech business @ElevateBio CEO & Chairman David Hallal talks his company's mission, the road ahead, and the potential impact these therapies could have on patients:
English
3
4
27
15.7K
Devin Quinlan
Devin Quinlan@devinquinlan·
@EricTopol Imo you can’t draw that conclusion from those error bars.. especially when exercise + liraglutide is no different from liraglutide alone
English
0
0
6
600
Eric Topol
Eric Topol@EricTopol·
To reduce systemic markers of chronic inflammation (such as IL-6) in people with obesity, a GLP-1 drug was not as good as exercise in a randomized trial vs placebo medicalxpress.com/news/2024-05-t…
Eric Topol tweet media
English
10
131
461
74.9K
Devin Quinlan
Devin Quinlan@devinquinlan·
Congrats to our new company Reunion Neuroscience on a $103M Series A! Reunion is a clinical-stage company developing novel psychedelic therapies for postpartum depression! endpts.com/a-once-public-…
English
0
0
3
371
Devin Quinlan
Devin Quinlan@devinquinlan·
What a headline! Brought me back to AP Bio. Also - a very accurate takeaway from this year's AACR. @BioCentury
Devin Quinlan tweet media
English
0
0
3
420
Devin Quinlan retweetledi
Rami Rahal
Rami Rahal@ratatat79·
J&J’s William Hait highlighting the burden on pharma to launch products : 40 phase 1 ➡️ 3 BLAs! Hence $2B+ per drug launched. #AACR24 “Path to Entrepreneurship” session
Rami Rahal tweet media
English
5
27
131
81.6K
Devin Quinlan
Devin Quinlan@devinquinlan·
Excited to announce our newest portfolio company - Firefly Bio! Debuting with $94M, Firefly is pioneering degrader-antibody conjugates as an evolution to ADCs. MPM co-led the Series A financing with Versant Ventures, alongside Decheng and Lilly fireflybiologics.com/press-release-…
English
1
1
14
959
Devin Quinlan retweetledi
MPM BioImpact
MPM BioImpact@MPMBioImpact·
MPM BioImpact is pleased to participate in the Series A financing of AstronauTx to develop novel treatments for Alzheimer’s disease and other neurodegenerative disorders. Read the press release: astronautx.bio/astronautx-clo…
English
1
1
4
927

Keşfet

@NewEnglandVC @kulesatony @Mykalt45 @BowTiedBiotech @Festivus159 @EricDai_BioE @davidkmyang @hannu